Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
Dermatology 2025, traveller dermatology, AI, High-Magnification Dermoscopy, hand eczema, vitiligo and psoriasis
JOURNALS
Start Learning
The future of dermatology: 4 predictions for 2025
JOURNALS
Start Learning
FDA approval of nemolizumab gives new treatment option for prurigo nodularis
touchFOCUS
Start Learning
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
CE/CME ACCREDITED
JOURNALS
Start Learning
From Clinic to CNN: Dr. Shari Lipner’s Journey in Advancing Nail Disorders and Mentoring Future Leaders
chronic spontaneous urticaria dupilumab
JOURNALS
Start Learning
Pooled phase III data reinforce dupilumab’s efficacy in H1-antihistamine refractory chronic spontaneous urticaria
androgenic alopecia, ET-02
JOURNALS
Start Learning
ET-02 shows promising 6-fold increase in hair growth in androgenic alopecia
Early-onset atopic dermatitis
JOURNALS
Start Learning
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
CONFERENCE HUB
Start Learning
Novel, oral TYK2 inhibitor, ESK-001, reports improved efficacy with prolonged use in plaque psoriasis
touchMEETING HIGHLIGHTS
Start Learning
ADVENT at ESPD 2024: Type 2 Inflammation in Atopic Dermatitis and the Benefits of Early Intervention
Sponsored content
Dr Raj Chovatiya (Associate Professor at Rosalind Franklin University Chicago, IL, USA) at the 2025 American Academy of Dermatology (AAD) Annual Meeting to discuss key late-breaking data on three promising therapies—ESK001, icotrokinra, and rocatinlimab—for psoriasis and atopic dermatitis.
CONFERENCE HUB
Start Learning
#AAD25: Essential updates in atopic dermatitis and psoriasis

to view Favourites, Keep Notes and Track CME Credits

Favourites
Baricitinib 4 mg delivers rapid, significant hair growth in adolescents with severe alopecia areata
View
Pooled phase III data reinforce dupilumab’s efficacy in H1-antihistamine refractory chronic spontaneous urticaria
View
Global impact, Brazilian roots: Prof. Ensina’s journey leading innovation in allergy and immunology
View
Honouring Prof. Marcus Maurer
View
Pathophysiological mechanisms and emerging concepts in the management of Type 2 dermatological diseases
View
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
View
ADVENT at ESPD 2024: Type 2 Inflammation in Atopic Dermatitis and the Benefits of Early Intervention
View
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
View
New data in oral lichen planus shows LP-310 oral tacrolimus reduces pain, ulceration and inflammation
View
Navigating treatment choices in high-risk early-stage melanoma
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup